Last reviewed · How we verify
Immunotherapy - PD-1 Blocker
Immunotherapy - PD-1 Blocker is a Small molecule drug developed by Liza Villaruz, MD. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immunotherapy - PD-1 Blocker |
|---|---|
| Sponsor | Liza Villaruz, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer (PHASE2)
- Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (PHASE1)
- Lamivudine for Solid Tumors (PHASE1, PHASE2)
- Impact of Circadian Rhythm on Immunotherapy (PHASE2)
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) (PHASE2)
- Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (PHASE1)
- In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunotherapy - PD-1 Blocker CI brief — competitive landscape report
- Immunotherapy - PD-1 Blocker updates RSS · CI watch RSS
- Liza Villaruz, MD portfolio CI
Frequently asked questions about Immunotherapy - PD-1 Blocker
What is Immunotherapy - PD-1 Blocker?
Who makes Immunotherapy - PD-1 Blocker?
What development phase is Immunotherapy - PD-1 Blocker in?
Related
- Manufacturer: Liza Villaruz, MD — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing